Main Article Content
Background. Given the similarity of histopathological pattern of non-alcoholic fatty liver disease and alcoholic liver disease, it was proposed to combine these both diseases in one nosological form named «fatty liver disease». The purpose of this review was to evaluate the efficacy and safety of essential phospholipids for the treatment of fatty liver disease. Methodology. When performing this review, re-analysis of 25 studies included in the review K.J. Gundermann et al. (2016), has been made. In these studies, essential phospholipids were obtained from soybeans containing not less than 72 % phosphatidylcholine. Results. It was found that essential phospholipids reduce the severity of symptoms, including general malaise, fatigue, nausea, incidence of hepatic pain, abdominal distension, constipation, obesity index and skin-fold thickness when used in nonalcoholic fatty liver disease (20 studies). Essential phospholipids were found to improve biochemical blood plasma markers (liver function tests — alanine aminotransferase, serum glutamic oxalacetic transaminase, gamma-glutamyl transpeptidase, alkaline phosphatase, markers of lipid metabolism — total cholesterol, triglycerides, LDL cholesterol). Essential phospholipids improved the results of sonography and computed tomography of the liver in 60–75 % of patients. At the same time there observed the reverse of histopathological changes in the liver: decreased severity of steatosis, ballooning, intra-acinar and portal inflammation, leading to a decrease of the stage of steatohepatitis by Brunt classification. The total efficiency of the treatment with essential phospholipids was 80.5 %, while the total efficiency of the treatment in the placebo or «no treatment» groups was 27.9 % (p < 0.05). Similar results were obtained for the alcoholic liver disease (5 studies), but more researches are needed. Data from all the above cited studies suggest that the treatment of essential phospholipids was safe. Conclusion. In 25 clinical studies it was confirmed the effectiveness and safety of the essential phospholipids for the treatment of fatty liver disease.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Sass D.A., Chang P., Chopra K.B. Nonalcoholic fatty liver disease: a clinical review // Dig. Dis. Sci. — 2005. — Vol. 50, № 1. — P. 171-180.
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease / Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. // Mayo Clin. Proc. — 1980. — Vol. 55, № 7. — P. 434-438.
Partha P., Sayantan R. Alcoholic liver disease: a comprehensive review // EMJ. — 2016. — Vol. 1, № 2. — P. 85-92.
Völzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? // World J. Gastroenterol. — 2012. — Vol. 18, № 27. — P. 3492-3501.
Essential phospholipids // http://www.titanbiotechltd.com
PhosChol Prescribing Information // http://www.phoschol.com
Kidd P. Phosphatidylcholine: a superior protectant against liver damage // Alt. Med. Rev. — 1996. — Vol. 1, № 4. — P. 258-274.
Activity of essential phospholipids (EPL) from soybean in liver diseases / Gundermann K.J., Kuenker A., Kuntz E., Droździk M. // Pharmacol. Rep. — 2011. — Vol. 63, № 3. — P. 643-659.
Essential phospholipids in fatty liver: a scientific update / Gundermann K.J., Gundermann S., Drozdzik M., Mohan Prasad V.G. // Clin. Exp. Gastroenterol. — 2016. — Vol. 9. — P. 105-117.
Энерлив // http://compendium.com.ua
Multimodal treatment resulting in rapid improvement of fatty liver in obese patients / Watanabe A., Kobayashi M., Morishita N., Nagashima H. // Curr. Ther. Res. — 1988. — Vol. 43, № 2. — P. 239-246.
Randomised placebo-controlled double blind trial on «essential» phospholipids in the treatment of fatty liver associated with diabetes / Gonciarz Z., Besser P., Lelek E. et al. // Méd. Chir. Dig. — 1988. — Vol. 17, № 1. — P. 61-65.
Polyunsaturated phosphatidylcholine combined with vitamin B complex in the treatment of patients with disorders of the hepatobiliary function caused by unbalanced nutrition // Cairella M., Callisto F., Godi R., Marchini G. // Clin. Ter. — 1989. — Vol. 131, № 4. — P. 237-246.
Clinical progress of 51 fatty liver cases analyzed by liver function tests and ultrasonic screening and results of EPL administered cases / Koga S., Irisa T., Miyata Y. et al. // Prog. Med. — 1991. — Vol. 11, № 7. — P. 1891-1899.
A randomized controlled study of essential phospholipids (Essentiale capsules) in the treatment of fatty liver / Li J.H., Chen X.Y., Zhong C.F., Min J. // Infect. Dis. Info. — 2000. — Vol. 13, № 4. — P. 180-181.
Yin D., Kong L. Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus // Med. J.Q. Ilu. — 2000. — Vol. 15. — P. 277-278.
Ohbayashi H. Twelve-month chronic administration of polyenephosphatidylcholine (EPL®) for improving hepatic function of fatty liver patients // Prog. Med. — 2004. — Vol. 24, № 7. — P. 1751-1756.
Effect of essentiale in diabetic subjects with non-alcoholic fatty liver / Poongothai S., Karkuzhali K., Siva Prakash G. et al. // Int. J. Diab. Dev. Ctries. — 2005. — Vol. 25, № 1. — P. 12-19.
The therapeutic effect of polyenephosphatidylcholine (EPL) on NASH / Ohbayashi H., Fujimoto M., Yoshida M. et al. // Liver Bile Pancreas. — 2006. — Vol. 52, № 4. — P. 637-642.
Liang H. Treatment of fatty liver applying polyene phosphatidyl choline // Chin. Med. Factory Mine. — 2006. — Vol. 19, № 3. — P. 207-208.
Arvind N., Savaikar P., Rajkumar J.S. Therapy for NAFLD-comparative study of essential phospholipids vs ursodeoxycholic acid // Ind. J. Clin. Pract. — 2006. — Vol. 16, № 10. — P. 21-24.
Improvement of NASH with two-year treatment with oral polyenephosphatidylcholine / Ohbayashi H., Fujimoto M., Yamase H., Ito M. // J. Rural Med. — 2007. — Vol. 1. — P. 67-73.
Shen Z. Observation of efficacy in 100 patients with non-alcoholic fatty liver disease treated with Essentiale // Chin. J. Curr. Clin. Med. — 2007. — Vol. 5, № 8. — P. 693-694.
Application of essential phospholipids in complex therapy of steatohepatitis of the mixed origin / Buyeverov A.O., Yeshanu V.S., Mayevskaya M.V., Ivashkin V.T. // Klin. Persp. Gastroenterol. Hepatol. — 2008. — Vol. 1. — P. 17-22.
Clinical observation on polyene phosphatidyl choline and metformin in the treatment of type 2 diabetes and non-alcoholic fatty liver disease / Sun C., Zheng X., Tan Z. et al. // Clin. Focus. — 2008. — Vol. 23, № 17. — P. 1272-1273.
Zhuang X.S., Zhang Z.J. Study of ursodeoxycholic acid (UDCA) combined with polyene phosphatidylcholine in the treatment of non-alcoholic steatohepatitis // China Pract. Med. — 2009. — Vol. 4, № 10. — P. 11-12.
Zhou S.Y., Sun Z.Y. Therapeutic efficacy of polyunsaturated phosphatidylcholine on fatty liver disease // J. Clin. Hepatol. — 2010. — Vol. 26, № 3. — P. 286-287.
Effect of Xuezhikang capsule on serum tumor necrosis factor-α and interleukin‑6 in patients with nonalcoholic fatty liver disease and hyperlipidemia / Fan X., Deng Y., Ye L. et al. // Chin. J. Integr. Med. — 2010. — Vol. 16, № 2. — P. 119-123.
Guo X.L., Liang P.X., Xu Y.Q. Comparison of efficacies of diammonium glycyrrhizinate and polyene phosphatidylcholine on nonalcoholic steatohepatitis // Chin. J. New Drugs. — 2012. — Vol. 21, № 3. — P. 289-293.
Beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis accompanied by diabetes type 2. Results of prolonged randomized blinded prospective clinical study / Sas E., Grinevich V., Efimov O., Shcherbina N. // J. Hepatol. — 2013. — Vol. 58. — P. S549.
Knüchel F. Double-blind study in patients with alcoholic fatty liver. The influence of «essential» phospholipids on enzyme behaviour and lipid composition of the serum // Med. Welt. — 1979. — Vol. 30, № 11. — P. 411-416.
Schüller Pérez A., Gonzáles San Martin F. Placebo-controlled study with polyunsaturated phosphatidylcholine in alcoholic steatosis of the liver // Med. Welt. — 1985. — Vol. 36, № 16. — P. 517-521.
Polyunsaturated phosphatidyl choline for acute alcoholic hepatitis: a double-blind, randomized, placebo-controlled trial / Panos M.Z., Polson R., Johnson R. et al. // Eur. J. Gastroenterol. Hepatol. — 1990. — Vol. 2, № 5. — P. 351-355.
Veterans Affairs Cooperative Study 391 Group. II. Veterans affairs cooperative study of polyenylphosphatidylcholine in alcoholic liver disease / Lieber C.S., Weiss D.G., Grozmann R. et al. // Alcohol. Clin. Exp. Res. — 2003. — Vol. 27, № 11. — P. 1765-1772.
Polyunsaturated phosphatidylcholine reduces insulin resistance and hepatic fibrosis in patients with alcoholic liver disease: results of randomized blinded prospective clinical study / Sas E., Grinevich V., Kravchuk U., Efimov O. // J. Hepatol. — 2011. — Vol. 54. — P. S207.